News
Bristol Myers Squibb Co. closed 26.69% short of its 52-week high of $63.33, which the company achieved on March 11th.
Bristol Myers Squibb Co. closed 25.25% below its 52-week high of $63.33, which the company reached on March 11th.
2d
Barchart on MSNWhat to Expect From Bristol-Myers Squibb's Q2 2025 Earnings ReportBristol-Myers Squibb is set to announce its second-quarter results by the end of July, and analysts expect a notable drop in ...
BofA cuts Bristol Myers' 2025 EPS and sales estimates slightly and flags medium-term pressure from generics, while ...
StockStory.org on MSN4d
Why Bristol-Myers Squibb (BMY) Shares Are Sliding TodayShares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 3.5% in the afternoon session after a cautious ...
Bristol Myers Squibb is undervalued despite challenges. Learn how BMY stock's strong pipeline, cash flow, and growth ...
BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. Find out ...
The general mood among these heavyweight investors is divided, with 33% leaning bullish and 66% bearish. Among these notable options, 3 are puts, totaling $202,924, and 6 are calls, amounting to ...
Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Bristol-Myers Squibb Company recently updated its ...
Bristol Myers Squibb has opened its radiopharmaceutical manufacturing facility in Indianapolis, which played a major role in ...
Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic versions of its blockbuster blood cancer drug Pomalyst off the market so it could ...
Shares of Bristol Myers Squibb Co. slid 3.42% to $46.86 Friday, on what proved to be an all-around dismal trading session for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results